QP101: Dual Payload ADCQP101: First-in-Class Dual-Payload HER2 ADC
Overview
QP101 is a next-generation HER2-targeted antibody–drug conjugate (ADC) that integrates two synergistic payloads: a proprietary CDK7 inhibitor (CDK7i) and a clinically validated topoisomerase I inhibitor (TOP1i). This dual mechanism enables QP101 to deliver superior anti-tumor efficacy while maintaining a favorable safety profile.
Rationale and Differentiation
Clinical experience with existing TOP1i ADCs has shown that treatment outcomes often depend on tumor DNA Damage Response (DDR) proficiency. QP101’s CDK7i payload transcriptionally suppresses DDR gene expression, thereby sensitizing cancer cells to TOP1i-induced DNA damage. This combination amplifies anti-tumor activity and allows for significantly lower TOP1i content—reducing systemic toxicity while maintaining or enhancing efficacy.
Key Advantages
• Synergistic Payloads – Mechanistically complementary CDK7i + TOP1i combination.
• Improved Therapeutic Index – Strong efficacy with reduced cytotoxic payload exposure.
• Broader Clinical Potential – Opportunity to move HER2-targeted ADC therapy into earlier lines and additional tumor types beyond traditional HER2-positive cancers.
Vision
QP101 represents a paradigm shift in ADC design—transitioning from “dual cytotoxics” to “targeted therapy + cytotoxic” synergy. Qurient aims to position QP101 as a best-in-class HER2 ADC with expanded market reach and durable clinical impact.
Poster
1. Enhancing potency through synergy: QP101, a novel HER2-targeting dual-payload ADC. (2025 AACR-NCI-EORTC poster)